- Home
- TRU vs MDGL Comparison
TRU vs MDGL Comparison
Compare TRU & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TRU | MDGL |
|---|---|---|
| Founded | 1968 | 2011 |
| Country | United States | United States |
| Employees | N/A | 915 |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.1B | 11.5B |
| IPO Year | 2013 | 2005 |
Fundamental Metrics
Financial Performance| Metric | TRU | MDGL |
|---|---|---|
| Price | $69.78 | $495.75 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 12 |
| Target Price | $90.73 | ★ $674.45 |
| AVG Volume (30 Days) | ★ 2.1M | 254.7K |
| Earning Date | 04-28-2026 | 05-06-2026 |
| Dividend Yield | ★ 0.71% | N/A |
| EPS Growth | ★ 60.00 | 41.32 |
| EPS | ★ 2.04 | N/A |
| Revenue | ★ $4,576,300,000.00 | $180,133,000.00 |
| Revenue This Year | $11.20 | $58.39 |
| Revenue Next Year | $8.00 | $48.55 |
| P/E Ratio | $34.09 | ★ N/A |
| Revenue Growth | ★ 9.38 | N/A |
| 52 Week Low | $65.24 | $265.00 |
| 52 Week High | $99.39 | $615.00 |
Technical Indicators
Market Signals| Indicator | TRU | MDGL |
|---|---|---|
| Relative Strength Index (RSI) | 44.72 | 44.00 |
| Support Level | $66.64 | $461.99 |
| Resistance Level | $75.82 | $502.97 |
| Average True Range (ATR) | 2.42 | 20.67 |
| MACD | -0.18 | -4.12 |
| Stochastic Oscillator | 33.85 | 10.80 |
Price Performance
Historical ComparisonAbout TRU TransUnion
TransUnion, along with Equifax and Experian, is one of the three leading credit bureaus in the United States, providing the consumer information that is the basis for granting credit. The company also provides fraud detection, marketing, and analytical services. TransUnion operates in over 30 countries. About 20%-25% of its revenue comes from international markets.
About MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.